Keywords: USA, FDA, CMS, Premarket evaluation, Biolocics public hearing, Biosimilars

USA’s CMS and FDA consider overlapping premarket evaluations, as latter schedules biologics hearing

Article | 21 September 2010

The US Food and Drug Administration and the Centers for Medicare and Medicaid Services (CMS) are considering establishing a process ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in